camrelizumab,rivoceranib
jiangsu hengrui pharmaceuticals,hlb bio group
['apatinib', 'camrelizumab']
 #asco23 #ec patients treated with combination of camrelizumab (pd-1i) + apatinib (vegfr2i) experienced a 44% response rate &amp; 91% control rate. #meded #oncology #endometrialcancer 
COR2ED bringing you Independent Medical Education developed 
by OBSTETRICS & GYNECOLOGY CONNECT, international experts in obstetrics and gynecology